Regeneron Pharmaceuticals Management
Management criteria checks 4/4
Regeneron Pharmaceuticals' CEO is Leonard Schleifer, appointed in Jan 1988, has a tenure of 38.25 years. total yearly compensation is $6.82M, comprised of 28.4% salary and 71.6% bonuses, including company stock and options. directly owns 2.35% of the company’s shares, worth $1.85B. The average tenure of the management team and the board of directors is 7.3 years and 19.3 years respectively.
Key information
Leonard Schleifer
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | 28.45% |
| CEO tenure | 38.3yrs |
| CEO ownership | 2.4% |
| Management average tenure | 7.3yrs |
| Board average tenure | 19.3yrs |
Recent management updates
Recent updates
Regeneron: Fairly Valued Now After A Stellar Upswing
Mar 11
Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.
Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Nov 19
Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think
Nov 09Regeneron: Still A Biotech Juggernaut
Apr 16Dupixent And EYLEA Will Open New Therapeutic Frontiers
Promising pipeline and Dupixent’s market expansion are expected to drive revenue growth and improve net margins.Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow
Apr 06Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Mar 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$5b |
| Sep 30 2025 | n/a | n/a | US$5b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$7m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$8m | US$2m | US$4b |
| Sep 30 2023 | n/a | n/a | US$4b |
| Jun 30 2023 | n/a | n/a | US$4b |
| Mar 31 2023 | n/a | n/a | US$4b |
| Dec 31 2022 | US$7m | US$2m | US$4b |
| Sep 30 2022 | n/a | n/a | US$5b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$6m | US$2m | US$8b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$4b |
| Dec 31 2020 | US$135m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$2b |
| Dec 31 2019 | US$21m | US$1m | US$2b |
Compensation vs Market: Leonard's total compensation ($USD6.82M) is below average for companies of similar size in the US market ($USD14.12M).
Compensation vs Earnings: Leonard's compensation has been consistent with company performance over the past year.
CEO
Leonard Schleifer (72 yo)
Dr. Leonard S. Schleifer, M.D., Ph D., Co-founded Regeneron Pharmaceuticals, Inc. in 1988 and has been its President and Chief Executive Officer since 1988 and is its Board Co-Chair since June 2023. He ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 38.3yrs | US$6.82m | 2.35% $ 1.9b | |
| Co-Founder | 25.3yrs | US$6.80m | 1.14% $ 897.4m | |
| Executive VP of Finance & CFO | 2.2yrs | US$6.27m | 0.021% $ 16.7m | |
| Executive VP of Research & Co-Chief Scientific Officer | 7.3yrs | US$8.36m | 0.051% $ 40.1m | |
| Executive VP and GM of Industrial Operations & Product Supply | 18yrs | US$8.66m | 0.034% $ 27.0m | |
| Senior Vice President of Quality Assurance & Operations | 1.3yrs | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Senior Vice President of Investor Relations & Strategic Analysis | no data | no data | no data | |
| Executive VP | 14.6yrs | US$7.13m | 0.041% $ 32.5m | |
| Senior VP & Chief Compliance Officer | 3.3yrs | no data | no data | |
| Executive Vice President of Human Resources | 10yrs | no data | no data | |
| Senior Vice President of Public Policy & Government Affairs | 5.3yrs | no data | no data |
Experienced Management: REGN's management team is seasoned and experienced (7.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 38.3yrs | US$6.82m | 2.35% $ 1.9b | |
| Co-Founder | 25.3yrs | US$6.80m | 1.14% $ 897.4m | |
| Lead Independent Director | 15.4yrs | US$769.77k | 0.0034% $ 2.7m | |
| Independent Director | 23.3yrs | US$719.77k | 0.015% $ 12.2m | |
| Independent Director | 34.8yrs | US$724.77k | 0.011% $ 8.6m | |
| Independent Director | 34.8yrs | US$709.77k | 0.0049% $ 3.8m | |
| Independent Director | 38.3yrs | US$724.77k | 0.032% $ 25.5m | |
| Independent Director | 9.3yrs | US$699.77k | 0.000010% $ 7.9k | |
| Independent Director | 3.5yrs | US$699.77k | 0% $ 0 | |
| Independent Director | 9.6yrs | US$714.77k | 0% $ 0 | |
| Independent Director | 9.6yrs | US$709.77k | 0.0017% $ 1.3m | |
| Independent Director | 2.6yrs | US$288.99k | 0% $ 0 |
Experienced Board: REGN's board of directors are seasoned and experienced ( 19.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 15:44 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Regeneron Pharmaceuticals, Inc. is covered by 51 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Brian Skorney | Baird |
| James Birchenough | Barclays |